Joseph R Habib, Benedict Kinny-Köster, Ammar A Javed, Poitr Zelga, Lily V Saadat, Rachel C Kim, Myrte Gorris, Valentina Allegrini, Shuichi Watanabe, Jeremy Sharib, Massimo Arcerito, Jörg Kaiser, Kelly J Lafaro, Min Tu, Manish Bhandre, Chanjuan Shi, Michael P Kim, Camilo Correa, Lois A Daamen, Paul E Oberstein, C Max Schmidt, Nader N Hanna, Peter Allen, Martin Loos, Shailesh V Shrikhande, I Quintus Molenaar, Isabella Frigerio, Matthew H G Katz, Kevin C Soares, Yi Miao, Marco Del Chiaro, Jin He, Thilo Hackert, Roberto Salvia, Markus W Büchler, Carlos Fernandez-Del Castillo, Marc G Besselink, Giovanni Marchegiani, Christopher L Wolfgang
PURPOSE: The benefit of adjuvant therapy for intraductal papillary mucinous neoplasm (IPMN)-derived pancreatic ductal adenocarcinoma (PDAC) remains unclear because of severely limited evidence. Although biologically distinct entities, adjuvant therapy practices for IPMN-derived PDAC are largely founded on pancreatic intraepithelial neoplasia-derived PDAC. We aimed to evaluate the role of adjuvant chemotherapy in IPMN-derived PDAC. METHODS: This international multicenter retrospective cohort study (2005-2018) was conceived at the Verona Evidence-Based Medicine meeting...
September 10, 2024: Journal of Clinical Oncology